Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for fibrosis and inflammation in HIV
NCT01928927Phase 2Completed
- Start
- Jan 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of telmisartan in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoints: Change in Percent Collagen I Deposition on Lymph Node Pathology at 48 weeks and Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology at 48 weeks. Started Jan 2014; status: completed.
02
Drugs
telmisartan
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01928927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928927.